NORTH TIDE CAPITAL, LLC
Follow13F filer, CIK 1557543, BOSTON, MA
NORTH TIDE CAPITAL, LLC reported $468,881,000 across 13 holdings for the quarter ended 2017-09-30, in a 13F-HR filed 2017-11-14. Its ten largest share positions make up 91.11% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-17-042427
- Period
- 2017-09-30
- Reported value
- $469M
- Holdings
- 13
- Top 10 weight
- 91.11%
- New
- 5
- Sold out
- 4
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| MCKadded | +350,000 | $53.8M |
| SUPERVALU INCnew | +2,000,001 | $43.5M |
| EXPRESS SCRIPTS HLDG COnew | +350,000 | $22.2M |
| CVSnew | +250,000 | $20.3M |
| INVACARE CORPnew | +1,023,000 | $16.1M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| TIVITY HEALTH INCreduced | -1,750,000 | -$71.4M |
| GILDreduced | -500,000 | -$40.5M |
| SUPERVALU INCexited | -10,000,000 | -$32.9M |
| IMPAX LABORATORIES INCexited | -1,000,000 | -$16.1M |
| SEMreduced | -500,000 | -$9.6M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2017
Share positions as resolved from 13F-HR 0001140361-17-042427, largest first. % of portfolio is the value over $468,881,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| SEMSELECT MED HLDGS CORP | 4,500,000 | $86.4M | 18.43% | -500,000 | Timeline | ||
| MCKMCKESSON CORP | 500,000 | $76.8M | 16.38% | +350,000 | Timeline | ||
| SUPERVALU INCSUPERVALU INC | 2,000,001 | $43.5M | 9.28% | new | |||
| MYLAN NVMYLAN NV | 1,350,000 | $42.4M | 9.03% | +350,000 | |||
| GILDGILEAD SCIENCES INC | 500,000 | $40.5M | 8.64% | -500,000 | Timeline | ||
| ENDO INTL PLCENDO INTL PLC | 4,000,000 | $34.3M | 7.31% | +1,000,000 | |||
| TIVITY HEALTH INCTIVITY HEALTH INC | 750,000 | $30.6M | 6.53% | -1,750,000 | |||
| PRGOPERRIGO CO PLC | 300,000 | $25.4M | 5.42% | 0 | Timeline | ||
| THCTENET HEALTHCARE CORP | 1,534,200 | $25.2M | 5.38% | +534,200 | Timeline | ||
| EXPRESS SCRIPTS HLDG COEXPRESS SCRIPTS HLDG CO | 350,000 | $22.2M | 4.73% | new | |||
| CVSCVS HEALTH CORP | 250,000 | $20.3M | 4.34% | new | Timeline | ||
| INVACARE CORPINVACARE CORP | 1,023,000 | $16.1M | 3.44% | new | |||
| PACBPACIFIC BIOSCIENCES CALIF IN | 1,000,000 | $5.25M | 1.12% | new | Timeline |
Sold out in Q3 2017
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| SUPERVALU INCSUPERVALU INC | 10,000,000 | $32.9M | shares |
| IMPAX LABORATORIES INCIMPAX LABORATORIES INC | 1,000,000 | $16.1M | shares |
| BIOSCRIP INCBIOSCRIP INC | 3,000,000 | $8.14M | shares |
| VIVUS INCVIVUS INC | 5,000,000 | $6.1M | shares |
How Q3 2017 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001140361-17-042427 | base | 2017-11-14 | acceptance time not in the bulk data set |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001140361-17-042427 | Quarter ended 2017-09-30 | 2017-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-17-031616 | Quarter ended 2017-06-30 | 2017-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-17-020333 | Quarter ended 2017-03-31 | 2017-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-17-006734 | Quarter ended 2016-12-31 | 2017-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-16-086172 | Quarter ended 2016-09-30 | 2016-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-16-076492 | Quarter ended 2016-06-30 | 2016-08-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-16-065427 | Quarter ended 2016-03-31 | 2016-05-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-16-053279 | Quarter ended 2015-12-31 | 2016-02-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-15-041521 | Quarter ended 2015-09-30 | 2015-11-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-15-032072 | Quarter ended 2015-06-30 | 2015-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-15-020122 | Quarter ended 2015-03-31 | 2015-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-15-006602 | Quarter ended 2014-12-31 | 2015-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-14-042103 | Quarter ended 2014-09-30 | 2014-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-14-032579 | Quarter ended 2014-06-30 | 2014-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-14-021406 | Quarter ended 2014-03-31 | 2014-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-14-007532 | Quarter ended 2013-12-31 | 2014-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-13-042524 | Quarter ended 2013-09-30 | 2013-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001140361-13-032455 | Quarter ended 2013-06-30 | 2013-08-14 | acceptance time not in the bulk data set |